This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday - Chewy (NYSE:CHWY), Novo N

Energy Fuels (UUUU) rose 9% to $8.25 after securing $126M in conditional financing for its Australian rare earth project. NuScale Power (SMR) and Oklo (OKLO) also gained 7% and 6% respectively. The financing, pending final approvals, aims to advance the Donald Rare Earth Project, crucial for EV and defense magnets.

Eli Lilly (LLY) won a preliminary ruling against Novo Nordisk's request to block its ads for Zepbound and Mounjaro. The judge found insufficient evidence of harm to Novo's sales or reputation. Both companies compete in a multi-billion-dollar weight-loss market. The case continues, with Novo seeking to prove false advertising claims.

A US judge rejected Novo Nordisk's request to stop Eli Lilly's weight-loss drug ads, which Novo claimed were misleading. The case involves a market with annual sales in the tens of billions.

A US judge denied Novo Nordisk's request to block Eli Lilly's weight-loss drug ads, ruling the harm claim insufficient. Novo Nordisk sued in July, alleging false advertising. Eli Lilly denies wrongdoing. The US weight-loss drug market is projected to exceed $100B by 2030.

Eli Lilly's tirzepatide (Mounjaro/Zepbound) outperformed Novo Nordisk's Wegovy in a weight-loss trial, with users losing 20.2% body weight vs. 13.7%. Mounjaro became the world's top-selling drug, generating $8.7B in Q1 2026. U.S. obesity rates declined, and drug usage surged in the UK. Both drugs were initially developed for diabetes.

Novo Nordisk (NVO) received FDA approval for Awiqli, a once-weekly insulin for children aged 10+ with type 2 diabetes. The treatment reduces weekly injections from seven to one. Approval followed clinical studies in adults and a pharmacokinetic study in children. Novo Nordisk reports 93.7% of net sales from diabetes and obesity treatments, with 56% of sales from the U.S.